Vyepti (eptinezumab) for chronic migraine (off-label use potential)

Type: drug

Status: FDA Approved (for migraine)

Developer: Lundbeck

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026